Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results
Gold, J, Marta, MC, Meier, UC, Christensen, T, Miller, D, Altmann, D, Holden, D, Bianchi, L, Adiutori, R, MacManus, D, Yousry, T, Schmierer, K, Turner, B & Giovannoni, G 2016, ' Phase 2 baseline versus treatment clinical trial of the HIV drug Raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results ', Multiple Sclerosis Journal, vol. 22 SIII, pp. 188-189 . Aarhus University ResearcherID